Division of Pharmaceutics, Osaka University of Pharmaceutical Sciences, Osaka 569-1094, Japan.
Arch Pharm Res. 2012 Jun;35(6):1055-64. doi: 10.1007/s12272-012-0613-x. Epub 2012 Jun 30.
While a great deal of information of drug-drug interactions is known, most concern Western drugs. Relatively little is known of the interactions between Western drugs and traditional drugs such as Kampo extract medicines (Japanese medicines modified from traditional Chinese medicines). This study investigated the effects of the marketed Kampo extract medicines, Senkyu-cha-cho-san and Sokei-kakketsu-to, on the intestinal absorption of CYP or P-glycoprotein (P-gp) in vivo. Midazolam, a CYP3A substrate drug, or talinolol, a P-gp substrate drug, was orally administered to rats with each of these Kampo extract medicines. Senkyu-cha-chosan or Sokei-kakketsu-to administered as a standard regimen did not obviously affect Cmax and area under the curve (AUC) of midazolam, although both Kampo extract medicines contained notopterol, a potent CYP3A4 inhibitor in vitro. The results implied a lack of potent drug-drug interactions between both Kampo extract medicines and CYP3A substrate drugs. Concomitant administration of each Kampo extract medicine unexpectedly showed the tendency to decrease Cmax and AUC of talinolol. Decreased intestinal absorption of talinolol might be caused, not by the inhibition of P-gp, but by the inhibition of organic anion transporting peptides by both Kampo extract medicines.
虽然已经了解到很多关于药物相互作用的信息，但大多数都涉及西药。对于西药与坎帕提取物药物（从中药改良而来的日本药物）等传统药物之间的相互作用，了解相对较少。本研究调查了市售坎帕提取物药物参薬茶茶三和硝甲煎剂对体内 CYP 或 P-糖蛋白 (P-gp) 肠吸收的影响。咪达唑仑是一种 CYP3A 底物药物，或他林洛尔是一种 P-gp 底物药物，这两种药物分别与这些坎帕提取物药物一起口服给予大鼠。标准方案给予参薬茶茶三和硝甲煎剂并没有明显影响咪达唑仑的 Cmax 和 AUC，尽管这两种坎帕提取物药物都含有体外强效 CYP3A4 抑制剂异土木香内酯。结果表明，这两种坎帕提取物药物与 CYP3A 底物药物之间不存在明显的药物相互作用。出乎意料的是，同时给予每种坎帕提取物药物会降低他林洛尔的 Cmax 和 AUC。他林洛尔肠吸收减少可能不是由 P-gp 抑制引起的，而是由两种坎帕提取物药物抑制有机阴离子转运肽引起的。
